Globe Newswire (Mon, 14-Sep 8:00 AM ET)
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
Globe Newswire (Wed, 26-Aug 7:00 AM ET)
Globe Newswire (Thu, 20-Aug 7:00 AM ET)
Globe Newswire (Mon, 17-Aug 7:30 AM ET)
Radiopharm Theranostics Reports Business Update
Globe Newswire (Fri, 31-Jul 7:00 AM ET)
Globe Newswire (Fri, 24-Jul 7:15 AM ET)
Globe Newswire (Wed, 22-Jul 7:05 AM ET)
Globe Newswire (Wed, 22-Jul 7:00 AM ET)
Radiopharm's RAD101 Shows 92% Success Rate in Detecting Brain Metastases—Pivotal Study Set for 2026
Market Chameleon (Mon, 15-Dec 4:51 AM ET)
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Radiopharm Theranostics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol RADX.
As of September 25, 2026, RADX stock price climbed to $1.65 with 37,466 million shares trading.
RADX has a beta of 0.30, meaning it tends to be less sensitive to market movements. RADX has a correlation of 0.00 to the broad based SPY ETF.
RADX has a market cap of $24.08 million. This is considered a Sub-Micro Cap stock.
RADX has underperformed the market in the last year with a price return of -71.3% while the SPY ETF gained +18.4%. RADX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -61.9% and -16.7%, respectively, while the SPY returned +5.3% and +1.2%, respectively.
RADX support price is $1.43 and resistance is $1.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RADX shares will trade within this expected range on the day.